Continuing Medical Education

ESMO-MORA Accreditation

This Congress has been awarded the ESMO label and 25 ESMO-MORA category 1 points. Participants will receive a certificate of attendance at the end of the Congress.

EACCME Accreditation Statement

The ESMO 14th World Congress on Gastrointestinal Cancer ' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 'ESMO 14th World Congress on Gastrointestinal Cancer ' is designated for a maximum of (or 'for up to') 20 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Who Should Attend:

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Learning Objectives:

After attending this Congress, participants should be able to:

• Identify current controversies in the management of patients with gastric or esophageal cancers
• Discuss contemporary treatment options for patients with gastric or esophageal cancers
• Comment on available treatment options for rare gastrointestinal and neuroendocrine tumors
• Recognize the epidemiology and pathogenesis of hepatocellular carcinoma
• Discuss management of patients with cancer of the liver
• Understand adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
• Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
• Generalize the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
• Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
• Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results
• Identify treatment strategies for rectal cancer
• Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancers

Congress Secretariat

11675 Rainwater Drive, Suite 600
Alpharetta, Georgia 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: info@imedex.com
www.imedex.com
www.worldgicancer.com

For registration inquiries:

Tel.: +1 855-276-6855
Email: registration@imedex.com

 

©2011 Imedex®, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.